Characteristic | Eligible patients |
---|---|
(N = 727) | |
Sex, n (%), male | 478 (65.8) |
Age, mean (SD), years (n = 725) | 67.2 (8.8) |
BMI, mean (SD), kg/m2 (n = 720) | 26.4 (5.2) |
Current smoker, n (%) | 202 (27.8) |
Smoking history, mean (SD), pack-years (n = 723) | 43.1 (24.8) |
Post-bronchodilator FEV1, mean (SD), L (n = 696) | 1.4 (0.6) |
% predicted FEV1, mean (SD) (n = 718) | 52.8 (20.5) |
COPD severity, n (%) | |
GOLD group I (mild) | 63 (8.7) |
GOLD group II (moderate) | 265 (36.5) |
GOLD group III (severe) | 261 (35.9) |
GOLD group IV (very severe) | 73 (10.0) |
mMRC grade, mean (SD) | 1.8 (1.0) |
mMRC dyspnoea grade, n (%) | |
0 | 53 (7.3) |
1 | 244 (33.6) |
2 | 244 (33.6) |
3 | 140 (19.3) |
4 | 44 (6.1) |
Patients with an exacerbation in previous year, n (%) | 392 (53.9) |
Number of COPD exacerbations in previous year, mean (SD) (n = 724) | 1.2 (1.6) |
Current COPD medication, n (%)a | |
LABAs + LAMAs + ICS | 355 (48.8) |
LABAs + ICS | 100 (13.8) |
LABAs + LAMAs | 70 (9.6) |
LABAs alone | 66 (9.1) |
LAMAs alone | 50 (6.9) |
Short-acting bronchodilatorsb | 22 (3.0) |
LABAs + LAMAs + ICS + PDE4 inhibitor | 15 (2.1) |
LAMAs + ICS | 8 (1.1) |
Otherc | 19 (2.6) |
No treatment | 22 (3.0) |
Total CAT score, mean (SD) (n = 721) | 16.5 (8.1) |
CAT score category, n (%) | |
CAT score ≤10, n (%) | 187 (25.7) |
CAT score 11–20, n (%) | 305 (42.0) |
CAT score 21–30, n (%) | 187 (25.7) |
CAT score >30, n (%) | 42 (5.8) |
HADS anxiety score, mean (SD) (n = 710) | 6.1 (4.2) |
HADS depression score, mean (SD) (n = 714) | 5.5 (4.1) |
CASIS score, mean (SD) (n = 712) | 44.1 (19.1) |